Insider Buying: Smith & Nephew plc (LON:SN) Insider Buys 5,344 Shares of Stock

Smith & Nephew plc (LON:SN - Get Free Report) insider Rupert Soames acquired 5,344 shares of the company's stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of GBX 936 ($12.04) per share, for a total transaction of £50,019.84 ($64,367.31).

Smith & Nephew Stock Performance

Shares of LON:SN traded up GBX 20.20 ($0.26) during mid-day trading on Tuesday, hitting GBX 937.80 ($12.07). The stock had a trading volume of 2,163,490 shares, compared to its average volume of 343,671. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The stock has a market capitalization of £8.18 billion, a P/E ratio of 3,473.33, a PEG ratio of 0.46 and a beta of 0.62. The firm's 50-day simple moving average is GBX 1,114.30 and its 200 day simple moving average is GBX 1,078.95.

Analysts Set New Price Targets

Separately, Berenberg Bank reiterated a "buy" rating and issued a £145 ($186.59) price objective on shares of Smith & Nephew in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of GBX 3,956.20 ($50.91).

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.